Home
Medicines
Active Ingredients
Companies
DHPC
Advanced Search
Side Effect Reporting
Login
Search Medicine Database
Home
Medicines
Active Ingredients
Companies
DHPC
Advanced Search
Side Effect Reporting
Login
menu
Home
Active Ingredients
Daratumumab
Daratumumab
Medicine
Status
Monitoring
SPC
PIL
XPIL
Legal Category
Active Ingredient(s)
Company
DARZALEX 1,800 mg solution for injection
Updated
SPC
PIL
No
A
Daratumumab
Janssen Sciences Ireland (a Johnson & Johnson Company)
DARZALEX 20 mg/mL concentrate for solution for infusion.
Updated
SPC
PIL
No
A
Daratumumab
Janssen Sciences Ireland (a Johnson & Johnson Company)
Cookies
Direct Healthcare Professional Communications
Documents associated with this medicine were updated in the last 30 days.
Product subject to medical prescription which may not be renewed (A)
